Trials / Terminated
TerminatedNCT01195779
Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children
Observer-blind Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Adjuvanted Quadrivalent Influenza Candidate Vaccines (GSK2584786A) in Children Aged 6 to 35 Months
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 6 Months – 35 Months
- Healthy volunteers
- Accepted
Summary
The purpose of this observer-blind study is to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' influenza vaccine GSK2584786A in healthy children 6 to 35 months of age.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GSK Bio's influenza vaccine GSK2584786A, different formulations | Intramuscular injections |
| BIOLOGICAL | GSK Bio's influenza vaccine GSK2321138A | Intramuscular injections |
| BIOLOGICAL | Fluarix™ | Intramuscular injections |
Timeline
- Start date
- 2010-09-30
- Primary completion
- 2011-03-22
- Completion
- 2011-03-22
- First posted
- 2010-09-06
- Last updated
- 2020-10-30
- Results posted
- 2012-04-24
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT01195779. Inclusion in this directory is not an endorsement.